Lemtrada adverse events (AEs) may occur more frequently than previously understood, according to an August 2019 medical journal article.
This new Lemtrada drug safety information appeared in this article, “Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis”, published August 12, 2019 by BMC Research Notes. From the Abstract for this recent Lemtrada study report we get the following:
Results: We identified nine cases with a probable and one case with a possible causal relationship between [Lemtrada (alemtuzumab)] treatment and a fatal adverse event. Six of these patients died within one month after treatment; one from intracerebral hemorrhage, two from acute multiple organ failure and septic shock, one from listeriosis, one from pneumonia and one from agranulocytosis. Four patients died several months after administration of [Lemtrada (alemtuzumab)] from either autoimmune hepatitis, immune-mediated thrombocytopenia, autoimmune hemolytic anemia or agranulocytosis….
Of course, we will continue to watch for reports of Lemtrada adverse events going forward.[Read article in full at original source]